Aug. 19 at 6:23 PM
$ARWR Bullish on ARWR's long term prospects. ARO MAPT read out should be another proof that ARWR's platform can deliver across the blood brain barrier using a simple injection (rather than a spinal one). This will, in it self, be a big development even if the readout involves healthy volunteers since cross the blood brain barrier this easily means ARWR an get other medicines across as well. ARWR's public comments also suggest that (even better) they are anticipating a Tau reduction as well, which has implications for Alzheimer's treatment. ARWR has developed an engine delivering meds across multiple tissue types at a good annual rate introducing new trials. The bit picture here is that ARWR has a platform it can probably aim anywhere....and that, IMO, is a big deal that is more important over the long run.
